Affimed N.V. (AFMD)
| Market Cap | 599.18M |
| Revenue (ttm) | 24.03M |
| Net Income (ttm) | -36.37M |
| Shares Out | 64.24M |
| EPS (ttm) | -0.72 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $5.22 |
| Previous Close | $5.13 |
| Change ($) | 0.09 |
| Change (%) | 1.75% |
| Day's Open | 5.20 |
| Day's Range | 4.78 - 5.29 |
| Day's Volume | 2,041,692 |
| 52-Week Range | 1.42 - 7.48 |
Steven Cohen (Trades, Portfolio), the billionaire investor who leads Point72 Asset Management, disclosed earlier this week his firm upped its stake in Affimed NV (NASDAQ:AFMD) by 190.73%.
Affimed N.V. (NASDAQ: AFMD) has entered into a clinical research collaboration with Roche Holding AG (OTC: RHHBF) to explore the combination of Affimed's AFM24 with Roche's atezolizumab (Tecen...
Heidelberg, Germany, February 3, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced ...
Heidelberg, Germany, January 15, 2021 – Affimed N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate abilit...
Affimed (AFMD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Heidelberg, Germany, January 13, 2021 – Affimed N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate abilit...
Heidelberg, Germany, January 12, 2021 – Affimed N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate abilit...
Heidelberg, Germany, January 11, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today anno...
Heidelberg, Germany, January 11, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today anno...
Heidelberg, Germany, January 7, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today annou...
Affimed continues to amass a stockpile of partnerships and collaborations that amplifies the risk-reward profile for an AFMD investment. As a result, I am looking to accumulate a larger positi...
Heidelberg, Germany, December 7, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today anno...
The phase 1b study showed a complete response (CR) rate of 46% (objective response rate [ORR] of 88%) at the recommended dose level in patients with relapsed/refractory (R/R) Hodgkin lymphoma...
Affimed N.V. (AFMD) CEO Adi Hoess on Q3 2020 Results - Earnings Call Transcript
Affimed N.V.'s (AFMD) CEO Adi Hoess On Q3 2020 Results - Quick Version Earnings Call Transcript
Affimed N.V. (AFMD) delivered earnings and revenue surprises of 33.33% and 94.55%, respectively, for the quarter ended September 2020.
Shares of Affimed (NASDAQ:AFMD) rose 11.3% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 57.89% over the past year to ($0.08), whi...
Heidelberg, Germany, Novembe r 10 , 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today r...
Affimed to grant license to AFM32 with options for additional ICE® molecules directed against targets not included in Affimed's current pipeline
Virtual data presentation at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting on Wednesday, November 11, 2020
Exclusive collaboration to assess feasibility and activity of pre-manufactured, co-vialed, cryopreserved, off-the-shelf NK cell combination therapeutics targeting EGFR and additional targets
Heidelberg, Germany, November 4, 2020 – Affimed N.V., (NASDAQ: AFMD) a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, announce...
Heidelberg, Germany, November 4, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today anno...
Heidelberg, Germany, November 3, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced ...
Heidelberg, Germany, and Santa Ana, California, October 20, 2020 – Affimed N.V. (NASDAQ: AFMD) and NKMax America Inc., both clinical stage biotech companies focused on harnessing the power of ...
Heidelberg, Germany, October 14, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today anno...
Pilsen, Czech Republic, October 6, 2020 - AbCheck s.r.o., a leader in providing antibody drug discovery, engineering and optimization services to the biotech and pharmaceutical industry, today...
Heidelberg, Germany, October 6, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today annou...
Heidelberg, Germany, September 29, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today an...
Heidelberg, Germany, September 2, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today an...
Affimed N.V. (AFMD) CEO Adi Hoess on Q2 2020 Results - Earnings Call Transcript
Affimed N.V. (AFMD) delivered earnings and revenue surprises of -50.00% and -52.45%, respectively, for the quarter ended June 2020.
Shares of Affimed (NASDAQ:AFMD) moved higher by 4% in pre-market trading after the company reported Q2 results.
Heidelberg, Germany, August 11, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today repor...
Heidelberg, Germany, August 5, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today annou...
Heidelberg, Germany, August 4, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced to...
Affimed N.V. (AFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Unlike a lot of companies that are focused on the adaptive immune system, Affimed is developing a novel suite of products aimed at boosting innate immunity to fight cancer.
Heidelberg, Germany, July 10, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced tod...
Affimed: Updates To Thesis, Time To Gain Exposure To Innate Immuno-Oncology
As of late, it has definitely been a great time to be an investor of Affimed
Investors need to pay close attention to Affimed (AFMD) stock based on the movements in the options market lately.
Affimed N.V. (AFMD) CEO Adi Hoess on Q1 2020 Results - Earnings Call Transcript
Shares of Affimed (NASDAQ:AFMD) decreased 3.0% in pre-market trading after the company reported Q1 results.
Heidelberg, Germany, June 22, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announ...
Heidelberg, Germany, June 17, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announ...
Affimed (AFMD) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Mr. Smith brings broad financial management and US capital markets expertise
REDIRECT is a Registration-directed Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients with Relapsed or Refractory CD30 positive Peripheral T-cell Ly...
About AFMD
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which has completed Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-bindi... [Read more...]
| Industry Biotechnology | IPO Date Sep 12, 2014 |
| CEO Dr. Adi Hoess | Employees 137 |
| Stock Exchange NASDAQ | Ticker Symbol AFMD |
Financial Performance
In 2019, Affimed N.V.'s revenue was 21.39 million, a decrease of -9.88% compared to the previous year's 23.74 million. Losses were -32.37 million, 66.2% more than in 2018.
Analyst Forecasts
According to 5 analysts, the average rating for Affimed N.V. stock is "Strong Buy." The 12-month stock price forecast is 9.48, which is an increase of 81.61% from the latest price.